H.R. 9661 · 119th Congress (2025–2027)
Expedited Access to Biosimilars Act
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
CRS summary not yet available.
Referred to committee
Latest actionReferred to committee
This bill’s path
This is H.R. 9661’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. Nicholas A. Langworthy (R-NY-23)
- Cosponsors
2 cosponsors
1 original · 1 later
- Rep. Kim Schrier (D-WA-8)· Original · Jul 14, 2026
- Rep. Robert J. Wittman (R-VA-1)· Later · Jul 21, 2026
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Committees
Jul 20, 2026 · Markup
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Official title · Introduced in House
Expedited Access to Biosimilars Act
Display title, Short title · Introduced in House